Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
Discussion
We’re nearly two weeks into the new year and I’m wondering, how are your resolutions going? If your answer is, “Not so well,” take heart…
Discussion
There is a specific kind of silence that occurs only when there is bad news. This type of silence isn’t peaceful or calm. It is…
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body…
Discussion
I’m writing this a few days after the end of ASH 2025, the annual meeting of the American Society of Hematology. As I mentioned…
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.